Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-56P (RNA, U6 small nuclear 56, pseudogene) is a genomic sequence annotated as a pseudogene derived from the U6 family of small nuclear RNAs. U6 snRNA is an essential component of the spliceosome, involved in pre-mRNA splicing. However, RNU6-56P is a non-functional pseudogene, meaning it does not produce a functional snRNA molecule and has no known biological activity, disease relevance, or role as a drug target[1][6]. The canonical U6 snRNA family members are important for splicing, but pseudogenes like RNU6-56P are typically transcriptionally inactive or non-essential. There is no evidence that RNU6-56P is involved in any physiological or pathological process, nor does it interact with drugs or act as a biomarker.\n\nIf you require structured information on functional U6 snRNA (such as RNU6-1), that would differ significantly—RNU6-1 is a bona fide snRNA essential for mRNA splicing[4][5][9]. RNU6-56P, by contrast, is only a non-coding pseudogene copy and is not considered a molecular or therapeutic target in any recognized context[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 56, pseudogene (RNU6-56P).